Modern approaches to the treatment of atrial firillation in patients with diabetes mellitus

Posted on by adminLeave a comment

S.A. Serik, V.I. Strona
National Institute of Therapy L.T. Malaya NAMS of Ukraine, Kharkiv, Ukraine

The article analyzes the main clinical and theoretical data on the features of the treatment of atrial fibrillation (AF) in combination with diabetes mellitus (DM). Differentiated approaches to the correction of these cardiac arrhythmias in this category of patients are considered, among which the methods of first choice are hypoglycemic therapy and catheter ablation. Currently, in addition to metformin, which is the basis for the treatment of most patients with type 2 diabetes, new classes of drugs are used: sodium glucose co-transporter-2 (SGLT2) inhibitors, agonists of the receptor for glucagon-like peptide-1 (aGPP-1), dipeptidyl peptidase 4 (DPP-4) inhibitors. The results of randomized trials performed using these classes of drugs have shown different levels of cardiac efficacy and safety in the treatment of patients with AF.  

 Key Words: diabetes mellitus, atrial fibrillation, hypoglycemic drugs, catheter ablation, electric pulse therapy. 

https://doi.org/10.15407/internalmed2022.01.069 

Download.PDF (rus) 

For cite: 

Серик, С.А. Современные подходы к лечению фибрилляции предсердий у больных сахарным диабетом / С.А. Серик, В.И. Строна // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2022. – № 1. – С. 69-85. doi:  10.15407/internalmed2022.01.069   

Serik SA, Strona VI. Sovremennye podhody k lecheniyu fibrillyacii predserdij u bol’nyh saharnym diabetom. [Modern approaches to the treatment of atrial fibrillation in patients with diabetes mellitus]. Shidnoevr. z. vnutr. simejnoi med. 2022;1:69-85. Russian. doi: 10.15407/internalmed2022.01.069   

References: 

  1. Bilovol, O. M., Kniazkova, I. I. Shchodo pytannia pro vedennia litnoho patsiienta z fibryliatsiieiu peredserd// Liky Ukrainy. 2021;8(254):20—26. Ukrainian. https://doi. org/10.37987/1997-9894.2021.8(254).245797
  2. Zhuravlyova LV, Sokolnikova NV, Rogachova TA. Vzaiemozviazok tsukrovoho diabetu i porushen rytmu sertsia: fokus na spilni patofiziolohichni mekhanizmy i suchasni metody likuvannia. [The relationship between diabetes mellitus and heart rhythm disorders: a focus on common pathophysiological mechanisms and modern treatment strategies]. Shidnoevr. z. vnutr. simejnoi med. 2021;2:22-27. Ukrainian. doi: 10.15407/internalmed2021.02.022
  3. Koval S.M., Yushko K.O. Tsukrovyi diabet 2 typu ta sertsevo-sudynni zakhvoriuvannia. Chastyna I. Vyznachennia problemy, stratyfikatsiia kardiovaskuliarnoho ryzyku i osnovni napriamky profilaktyky sertsevo-sudynnykh zakhvoriuvan u khvorykh na tsukrovyi diabet 2 typu. Arteryalnaia hypertenzyia. 2020;13(5):11-19. Ukrainian
  4. Serik SA, Strona VI. Fibrillyaciya predserdij u bol’nykh sakharnym diabetom. [Atrial fibrillation in diabetic patients]. Shidnoevr. z. vnutr. simejnoi med. 2021;2:103-117. Russian. doi: 10.15407/internalmed2021.02.103
  5. Flomin Ju. V. , Get’man T. V. , Romanova E. N. , Irkin O.I. Antikoaguljantnaja terapija u pacientov s neklapannoj fibrilljaciej predserdij: kakimi innovacionnymi vozmozhnostjami my raspolagaem segodnja? Russsian. Avalible from https:// health-ua.com/article/42970-antikoagulyantnaya-terapiyau-patcientov-s-neklapannoj-fibrillyatciej-preds.
  6. Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) follow-on study. Diabetes Care. 2016;39(7):1089—1100. https://doi.org/10.2337/dc16-0024
  7. AlKindi F, Al-Omary H, Hussain Q, Al Hakim M, Chaaban A, Boobes Y. Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients. Transplantation Proceedings. 2020;52(1):175-178. http://dx.doi.org/10.1016/j.transproceed.2019.11.007
  8. Anabtawi A, Miles J. Metformin: Nonglycemic Effects and Potential Novel Indications. Endocrine Practice. 2016;22(8):999-1007. http://dx.doi.org/10.4158/ep151145.ra
  9. Anselmino M, Matta M, D’ascenzo F, Pappone C, Santinelli V, Bunch T, Neumann T, Schilling R, Hunter R, Noelker G, Fiala M, Frontera A, Thomas G, Katritsis D, Jais P, Weerasooriya R, Kalman J, Gaita F. Catheter ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and meta-analysis. Europace. 2015;17(10):1518-1525. http://dx.doi.org/10.1093/europace/euv214
  10. Asghar O, Alam U, A. Hayat S, Aghamohammadzadeh R, M. Heagerty A, A. Malik R. Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions. Current Cardiology Reviews. 2012;8(4):253-264. http://dx.doi.org/10.2174/157340312803760749
  11. Ashabi G, Khalaj L, Khodagholi F, Goudarzvand M, Sarkaki A. Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia. Metabolic Brain Disease. 2014;30(3):747-754. http://dx.doi.org/10.1007/s11011-014-9632-2
  12. Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies. Journal of Diabetes and its Complications. 2018;32(5):501-511. http://dx.doi.org/10.1016/j.jdiacomp.2018.02.004
  13. Azoulay L, Suissa S. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies. Diabetes Care. 2017;40(5):706-714. http://dx.doi.org/10.2337/dc16-1943
  14. Baker W, Beyer‐Westendorf J, Bunz T, Eriksson D, Meinecke A, Sood N, Coleman C. Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non‐valvular atrial fibrillation and type 2 diabetes. Diabetes, Obesity and Metabolism. 2019;21(9):2107-2114. http://dx.doi.org/10.1111/dom.13787
  15. Ball J, Carrington M, McMurray J, Stewart S. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. International Journal of Cardiology. 2013;167(5):1807-1824. http://dx.doi.org/10.1016/j.ijcard.2012.12.093
  16. Bannister C, Holden S, Jenkins-Jones S, Morgan C, Halcox J, Schernthaner G, Mukherjee J, Currie C. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes, Obesity and Metabolism. 2014;16(11):1165-1173. http://dx.doi.org/10.1111/dom.12354
  17. Bansilal S, Bloomgarden Z, Halperin J. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J. 2015;170:675-682. https://doi.org/10.1016/j.ahj.2015.07.006
  18. Barkas F, Elisaf M, Tsimihodimos V, Milionis H. Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis. Diabetes & Metabolism. 2017;43(1):1-8. http://dx.doi.org/10.1016/j.diabet.2016.10.006
  19. Bogossian H, Frommeyer G, Brachmann J, Lewalter T, Hoffmann E, Kuck K, Andresen D, Willems S, Spitzer S, Deneke T, Thomas D, Hochadel M, Senges J, Eckardt L, Lemke B. Catheter ablation of atrial fibrillation and atrial flutter in patients with diabetes mellitus: Who benefits and who does not? Data from the German ablation registry. International Journal of Cardiology. 2016;214:25-30. http://dx.doi.org/10.1016/j.ijcard.2016.03.069
  20. Böhm M, Slawik J, Brueckmann M, Mattheus M, George J, Ofstad A, Inzucchi S, Fitchett D, Anker S, Marx N, Wanner C, Zinman B, Verma S. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial. European Journal of Heart Failure. 2019;22(1):126-135. http://dx.doi.org/10.1002/ejhf.1663
  21. Bohne L, Johnson D, Rose R, Wilton S, Gillis A. The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights. Frontiers in Physiology. 2019;10:. http://dx.doi.org/10.3389/fphys.2019.00135
  22. Boolani H, ShanbergD, ChikkamV, LakkireddyD. Metformin associated atrial fibrillation — a case report. J. Atr. Fibrillation. 2011;4:411.
  23. Brambatti M, Darius H, Oldgren J, Clemens A, Noack H, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz M, Connolly S, Healey J. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. International Journal of Cardiology. 2015;196:127-131. http://dx.doi.org/10.1016/j.ijcard.2015.05.141
  24. Buse J, Wexler D, Tsapas A, Rossing P, Mingrone G, Mathieu C, D’Alessio D, Davies M. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2019;43(2):487-493. http://dx.doi.org/10.2337/dci19-0066
  25. Castilla-Guerra L, Fernandez-Moreno M, Leon-Jimenez D, Carmona-Nimo E. Antidiabetic drugs and stroke risk. Current evidence. European Journal of Internal Medicine. 2018;48:1-5. http://dx.doi.org/10.1016/j.ejim.2017.09.019
  26. Chang C, Yeh Y, Chan Y, Liu J, Chang S, Lee H, Wu L, Yen K, Kuo C, See L. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Cardiovascular Diabetology. 2017;16(1):. http://dx.doi.org/10.1186/s12933-017-0640-5
  27. Chang S, Wu L, Chiou M, Liu J, Yu K, Kuo C, Wen M, Chen W, Yeh Y, See L. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovascular Diabetology. 2014;13(1):. http://dx.doi.org/10.1186/s12933-014-0123-x
  28. Chao T, Leu H, Huang C, Chen J, Chan W, Lin S, Chen S. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. International Journal of Cardiology. 2012;156(2):199-202. http://dx.doi.org/10.1016/j.ijcard.2011.08.081
  29. Chao T, Suenari K, Chang S, Lin Y, Lo L, Hu Y, Tuan T, Tai C, Tsao H, Li C, Ueng K, Wu T, Chen S. Atrial Substrate Properties and Outcome of Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation Associated With Diabetes Mellitus or Impaired Fasting Glucose. The American Journal of Cardiology. 2010;106(11):1615-1620. http://dx.doi.org/10.1016/j.amjcard.2010.07.038
  30. Cheng Y, Leu H, Chen T, Chen C, Kuo C, Lee S, Kao C. Metformin-inclusive Therapy Reduces the Risk of Stroke in Patients with Diabetes: A 4-Year Follow-up Study. Journal of Stroke and Cerebrovascular Diseases. 2014;23(2):e99-e105. http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2013.09.001
  31. Cheung C, Sing C, Lau W, Li G, Lip G, Tan K, Cheung B, Chan E, Wong I. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population‐based cohort study. Cardiovascular Diabetology. 2021;20(1):. http://dx.doi.org/10.1186/s12933-021-01263-0
  32. Cosentino F, Grant P, Aboyans V. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. https://doi.org/10.1093/eurheartj/ehz486
  33. Díez-Villanueva P, Alfonso F. Atrial fibrillation in the elderly // J Geriatr Cardiol. — 2019. — Vol 16(1). — Р.49—53.
  34. Dormandy J, Charbonnel B, Eckland D. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet. 2005;366;1279-1289. https://doi.org/10.1016/S0140-6736(05)67528-9
  35. Ebert M, Stegmann C, Kosiuk J, Dinov B, Richter S, Arya A, Müssigbrodt A, Sommer P, Hindricks G, Bollmann A. Predictors, management, and outcome of cardioversion failure early after atrial fibrillation ablation. EP Europace. 2017;20(9):1428-1434. http://dx.doi.org/10.1093/europace/eux327
  36. Echouffo-Tcheugui J, Shrader P, Thomas L, Gersh B, Kowey P, Mahaffey K, Singer D, Hylek E, Go A, Peterson E, Piccini J, Fonarow G. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes. Journal of the American College of Cardiology. 2017;70(11):1325-1335. http://dx.doi.org/10.1016/j.jacc.2017.07.755
  37. Eikelboom J, Wallentin L, Connolly S, Ezekowitz M, Healey J, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser S, Diener H, Franzosi M, Huber K, Reilly P, Varrone J, Yusuf S. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. Circulation. 2011;123(21):2363-2372. http://dx.doi.org/10.1161/circulationaha.110.004747
  38. Einarson T, Acs A, Ludwig C, Panton U. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular Diabetology. 2018;17(1):. http://dx.doi.org/10.1186/s12933-018-0728-6
  39. Emdin C, Callender T, Cao J, Rahimi K. Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials. Europace. 2015;17(5):701-710. http://dx.doi.org/10.1093/europace/euv021
  40. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T, Cushman W, Goff D, Soliman E, Thomas A, Papademetriou V. Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). The American Journal of Cardiology. 2014;114(8):1217-1222. http://dx.doi.org/10.1016/j.amjcard.2014.07.045
  41. Fernandes G, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani R, Myerburg R, Goldberger J. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18(7):1098-1105. http://dx.doi.org/10.1016/j.hrthm.2021.03.028
  42. Fisher M, Petrie M, Ambery P, Donaldson J, Ye J, McMurray J. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. The Lancet Diabetes & Endocrinology. 2015;3(9):697-703. http://dx.doi.org/10.1016/s2213-8587(15)00233-8
  43. FORLEO G, MANTICA M, DE LUCA L, LEO R, SANTINI L, PANIGADA S, DE SANCTIS V, PAPPALARDO A, LAURENZI F, AVELLA A, CASELLA M, RUSSO A, ROMEO F, PELARGONIO G, TONDO C. Catheter Ablation of Atrial Fibrillation in Patients with Diabetes Mellitus Type 2: Results from a Randomized Study Comparing Pulmonary Vein Isolation Versus Antiarrhythmic Drug Therapy. Journal of Cardiovascular Electrophysiology. 2009;20(1):22-28. http://dx.doi.org/10.1111/j.1540-8167.2008.01275.x
  44. Fox C. Cardiovascular Disease Risk Factors, Type 2 Diabetes Mellitus, and the Framingham Heart Study. Trends in Cardiovascular Medicine. 2010;20(3):90-95. http://dx.doi.org/10.1016/j.tcm.2010.08.001
  45. Fu X, Pan Y, Cao Q, Li B, Wang S, Du H, Duan N, Li X. Metformin restores electrophysiology of small conductance calcium-activated potassium channels in the atrium of GK diabetic rats. BMC Cardiovascular Disorders. 2018;18(1):. http://dx.doi.org/10.1186/s12872-018-0805-5
  46. Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O’Neill E, Engel S, Kaufman K, Lai E. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovascular Diabetology. 2017;16(1):. http://dx.doi.org/10.1186/s12933-017-0593-8
  47. Giacchetti G, Sechi L, Rilli S, Carey R. The renin–angiotensin–aldosterone system, glucose metabolism and diabetes. Trends in Endocrinology & Metabolism. 2005;16(3):120-126. http://dx.doi.org/10.1016/j.tem.2005.02.003
  48. Goudis C, Korantzopoulos P, Ntalas I, Kallergis E, Liu T, Ketikoglou D. Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies. International Journal of Cardiology. 2015;184:617-622. http://dx.doi.org/10.1016/j.ijcard.2015.03.052
  49. Gourdie R, Dimmeler S, Kohl P. Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease. Nature Reviews Drug Discovery. 2016;15(9):620-638. http://dx.doi.org/10.1038/nrd.2016.89
  50. Granger C, Alexander J, McMurray J. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981-992. https://doi.org/10.1056/NEJMoa1107039
  51. Green J, Bethel M, Armstrong P. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2015;373:232-242. https://doi.org/10.1056/NEJMoa1501352
  52. GRÖNBERG T, HARTIKAINEN J, NUOTIO I, BIANCARI F, VASANKARI T, NIKKINEN M, YLITALO A, AIRAKSINEN K. Can We Predict the Failure of Electrical Cardioversion of Acute Atrial Fibrillation? The FinCV Study. Pacing and Clinical Electrophysiology. 2014;38(3):368-375. http://dx.doi.org/10.1111/pace.12561
  53. Gu J, Liu X, Wang X, Shi H, Tan H, Zhou L, Gu J, Jiang W, Wang Y. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace. 2011;13(9):1256-1261. http://dx.doi.org/10.1093/europace/eur131
  54. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger C, Hanna M, Held C, Husted S, Hylek E, Jansky P, Lopes R, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. European Heart Journal. 2014;35(28):1864-1872. http://dx.doi.org/10.1093/eurheartj/ehu046
  55. Harada M, Nattel S. Implications of Inflammation and Fibrosis in Atrial Fibrillation Pathophysiology. Cardiac Electrophysiology Clinics. 2021;13(1):25-35. http://dx.doi.org/10.1016/j.ccep.2020.11.002
  56. Hernandez A, Green J, Janmohamed S. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A doubleblind, randomised placebo-controlled trial. Lancet. 2018;392:1519-1529. https://doi.org/10.1016/S0140-6736(18)32261-X
  57. Hindricks G, Potpara T, Dagres N. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart RhythmAssociation (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. https://doi.org/10.1093/eurheartj/ehaa612
  58. Homan E, Reyes M, Hickey K, Morrow J. Clinical Overview of Obesity and Diabetes Mellitus as Risk Factors for Atrial Fibrillation and Sudden Cardiac Death. Frontiers in Physiology. 2019;9:. http://dx.doi.org/10.3389/fphys.2018.01847
  59. Hylek E, Held C, Alexander J. Major Bleeding in Patients with Atrial Fibrillation Receiving Apixaban or Warfarin in the ARISTOTLE Trial: Predictors, Characteristics, and Clinical Outcomes. JACC. 2014;63:2141-2147. https://doi.org/10.1016/j.jacc.2014.02.549
  60. Imprialos K, Boutari C, Stavropoulos K, Doumas M, Karagiannis A. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. Journal of Neurology, Neurosurgery & Psychiatry. 2016;88(3):249-253. http://dx.doi.org/10.1136/jnnp-2016-314704
  61. Iravanian S, Dudley S. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm. 2008;5(6):S12-S17. http://dx.doi.org/10.1016/j.hrthm.2008.02.025
  62. Ito I, Hayashi Y, Kawai Y, Iwasaki M, Takada K, Kamibayashi T, Yamatodani A, Mashimo T. Diabetes Mellitus Reduces the Antiarrhythmic Effect of Ion Channel Blockers. Anesthesia & Analgesia. 2006;103(3):545-550. http://dx.doi.org/10.1213/01.ane.0000229709.29185.88
  63. January C, Wann L, Calkins H. 2019 AHA/ACC/ HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Heart Rhythm. 2019;140(2):125-151. https://doi.org/10.1161/CIR.0000000000000665
  64. Joy N, Tate D, Younk L, Davis S. Effects of Acute and Antecedent Hypoglycemia on Endothelial Function and Markers of Atherothrombotic Balance in Healthy Humans. Diabetes. 2015;64(7):2571-2580. http://dx.doi.org/10.2337/db14-1729
  65. Julius S, Kjeldsen S, Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The value randomised trial. ACC Current Journal Review. 2004;13(9):19. http://dx.doi.org/10.1016/j.accreview.2004.08.044
  66. Kamel H, Okin P, Elkind M, Iadecola C. Atrial Fibrillation and Mechanisms of Stroke. Stroke. 2016;47(3):895-900. http://dx.doi.org/10.1161/strokeaha.115.012004
  67. Letsas K, Karamichalakis N, Vlachos K, Georgopoulos S, Bakalakos A, Efremidis M, Sideris A. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vascular Health and Risk Management. 2015;:555. http://dx.doi.org/10.2147/vhrm.s83664
  68. Kernan W, Viscoli C, Furie K. Pioglitazone After Ischemic Stroke or Transient Ischemic Attack. Journal of Vascular Surgery. 2016;64(1):260. http://dx.doi.org/10.1016/j.jvs.2016.05.060
  69. Kim I, Kim H, Kim T, Uhm J, Joung B, Lee M, Pak H. Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis. Journal of Cardiology. 2018;72(2):105-112. http://dx.doi.org/10.1016/j.jjcc.2018.01.015
  70. Kim I, Kim H, Kim T, Uhm J, Joung B, Lee M, Pak H. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis. Journal of Cardiology. 2018;72(4):284-291. http://dx.doi.org/10.1016/j.jjcc.2018.03.009
  71. Kim Y, Han K, Choi J, Boo K, Kim D, Oh S, Lee K, Shim J, Kim J, Kim Y. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. Cardiovascular Diabetology. 2019;18(1):. http://dx.doi.org/10.1186/s12933-019-0932-z
  72. Kloosterman M, Oldgren J, Conen D, Wong J, Connolly S, Avezum A, Yusuf S, Ezekowitz M, Wallentin L, Ntep-Gweth M, Joseph P, Barrett T, Tanosmsup S, McIntyre W, Lee S, Parkash R, Amit G, Grinvalds A, Van Gelder I, Healey J. Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. EP Europace. 2020;22(6):870-877. http://dx.doi.org/10.1093/europace/euz360
  73. Korantzopoulos P, Kokkoris S, Kountouris E, Protopsaltis I, Siogas K, Melidonis A. Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy. International Journal of Cardiology. 2008;125(3):e51-e53. http://dx.doi.org/10.1016/j.ijcard.2006.12.063
  74. Kunte H, Schmidt S, Eliasziw M, del Zoppo G, Simard J, Masuhr F, Weih M, Dirnagl U. Sulfonylureas Improve Outcome in Patients With Type 2 Diabetes and Acute Ischemic Stroke. Stroke. 2007;38(9):2526-2530. http://dx.doi.org/10.1161/strokeaha.107.482216
  75. Lee M, Saver J, Liao H, Lin C, Ovbiagele B. Pioglitazone for Secondary Stroke Prevention. Stroke. 2017;48(2):388-393. http://dx.doi.org/10.1161/strokeaha.116.013977
  76. Leonard C, Hennessy S, Han X, Siscovick D, Flory J, Deo R. Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends in Endocrinology & Metabolism. 2017;28(8):561-586. http://dx.doi.org/10.1016/j.tem.2017.04.003
  77. Li W, Chen X, Xu L, Li Y, Luo B. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovascular Diabetology. 2020;19(1):. http://dx.doi.org/10.1186/s12933-020-01105-5
  78. Li Y, Miyazawa K, Wolff A, Zubaid M, Alsheikh-Ali A, Sulaiman K, Lip G. One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry. International Journal of Cardiology. 2019;274:158-162. http://dx.doi.org/10.1016/j.ijcard.2018.08.091
  79. Liou Y, Yang F, Chen H, Jong G. Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study. PLOS ONE. 2018;13(8):e0197245. http://dx.doi.org/10.1371/journal.pone.0197245
  80. Lip GY, Apostolakis S. Atrial fibrillation (acute onset). BMJ Clin Evid. 2014;2014:0210.
  81. Lip G. The ABC pathway: an integrated approach to improve AF management. Nature Reviews Cardiology. 2017;14(11):627-628. http://dx.doi.org/10.1038/nrcardio.2017.153
  82. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—Study Results. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/results/ NCT01179048.
  83. Liu R, Wang H, Xu B, Chen W, Turlova E, Dong N, Sun C, Lu Y, Fu H, Shi R, Barszczyk A, Yang D, Jin T, Mannucci E, Feng Z, Sun H. Cerebrovascular Safety of Sulfonylureas: The Role of KATP Channels in Neuroprotection and the Risk of Stroke in Patients With Type 2 Diabetes. Diabetes. 2016;65(9):2795-2809. http://dx.doi.org/10.2337/db15-1737
  84. Lopes R, Al-Khatib S, Wallentin L, Yang H, Ansell J, Bahit M, De Caterina R, Dorian P, Easton J, Erol C, Ezekowitz J, Gersh B, Granger C, Hohnloser S, Horowitz J, Hylek E, McMurray J, Mohan P, Vinereanu D, Alexander J. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. The Lancet. 2012;380(9855):1749-1758. http://dx.doi.org/10.1016/s0140-6736(12)60986-6
  85. Marso S, Bain S, Consoli A, Eliaschewitz F, Jódar E, Leiter L, Lingvay I, Rosenstock J, Seufert J, Warren M, Woo V, Hansen O, Holst A, Pettersson J, Vilsbøll T. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19):1834-1844. http://dx.doi.org/10.1056/nejmoa1607141
  86. Marx N, Walcher D, Raichle C, Aleksic M, Bach H, Grüb M, Hombach V, Libby P, Zieske A, Homma S, Strong J. C-Peptide Colocalizes with Macrophages in Early Arteriosclerotic Lesions of Diabetic Subjects and Induces Monocyte Chemotaxis In Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24(3):540-545. http://dx.doi.org/10.1161/01.atv.0000116027.81513.68
  87. Mentias A, Shantha G, Adeola O, Barnes G, Narasimhan B, Siontis K, Levine D, Sah R, Giudici M, Vaughan Sarrazin M. Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis. American Heart Journal. 2019;214:158-166. http://dx.doi.org/10.1016/j.ahj.2019.05.003
  88. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism. 2013;15(10):938-953. http://dx.doi.org/10.1111/dom.12116
  89. Monami M, Nreu B, Scatena A, Giannini S, Andreozzi F, Sesti G, Mannucci E. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. Journal of Endocrinological Investigation. 2017;40(11):1251-1258. http://dx.doi.org/10.1007/s40618-017-0698-7
  90. Moss A, Dimitropoulos G, Connolly D, Lip G. Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. Expert Opinion on Pharmacotherapy. 2017;18(11):1101-1114. http://dx.doi.org/10.1080/14656566.2017.1350647
  91. Naser N, Dilic M, Durak A, Kulic M, Pepic E, Smajic E, Kusljugic Z. The Impact of Risk Factors and Comorbidities on The Incidence of Atrial Fibrillation. Materia Socio Medica. 2017;29(4):231. http://dx.doi.org/10.5455/msm.2017.29.231-236
  92. Nreu B, Dicembrini I, Tinti F, Sesti G, Mannucci E, Monami M. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases. 2020;30(7):1106-1114. http://dx.doi.org/10.1016/j.numecd.2020.03.013
  93. Ntaios G, Papavasileiou V, Diener H, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. International Journal of Stroke. 2017;12(6):589-596. http://dx.doi.org/10.1177/1747493017700663
  94. Ostropolets A, Elias P, Reyes M, Wan E, Pajvani U, Hripcsak G, Morrow J. Metformin Is Associated With a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas. Circulation: Arrhythmia and Electrophysiology. 2021;14(3):. http://dx.doi.org/10.1161/circep.120.009115
  95. Ou H, Chang K, Li C, Wu J. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Cardiovascular Diabetology. 2016;15(1):. http://dx.doi.org/10.1186/s12933-016-0350-4
  96. Pallisgaard J, Brooks M, Chaitman B, Boothroyd D, Perez M, Hlatky M. Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease. The American Journal of Medicine. 2018;131(7):805-812. http://dx.doi.org/10.1016/j.amjmed.2018.02.026
  97. Pallisgaard J, Lindhardt T, Staerk L, Olesen J, Torp-Pedersen C, Hansen M, Gislason G. Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study. European Heart Journal – Cardiovascular Pharmacotherapy. 2016;:. http://dx.doi.org/10.1093/ehjcvp/pvw036
  98. Palmer SC., Tendal B., Mustafa RA. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2022;:o109. http://dx.doi.org/10.1136/bmj.o109
  99. Patti G, Di Gioia G, Cavallari I, Nenna A. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials. Diabetes/Metabolism Research and Reviews. 2017;33(3):e2876. http://dx.doi.org/10.1002/dmrr.2876
  100. Pfeffer M, Claggett B, Diaz R, Dickstein K, Gerstein H, Køber L, Lawson F, Ping L, Wei X, Lewis E, Maggioni A, McMurray J, Probstfield J, Riddle M, Solomon S, Tardif J. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine. 2015;373(23):2247-2257. http://dx.doi.org/10.1056/nejmoa1509225
  101. Qin D, Leef G, Alam M, Rattan R, Munir M, Patel D, Khattak F, Adelstein E, Jain S, Saba S. Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation. Journal of Cardiology. 2016;67(5):471-476. http://dx.doi.org/10.1016/j.jjcc.2015.07.001
  102. Razavi Nematollahi L, Kitabchi A, Stentz F, Wan J, Larijani B, Tehrani M, Gozashti M, Omidfar K, Taheri E. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism. 2009;58(4):443-448. http://dx.doi.org/10.1016/j.metabol.2008.10.018
  103. Reiff S, Fava S. All-cause mortality in patients on sulphonylurea monotherapy compared to metformin monotherapy in a nation-wide cohort. Diabetes Research and Clinical Practice. 2019;147:62-66. http://dx.doi.org/10.1016/j.diabres.2018.10.014
  104. Ren H, Shao Y, Wu C, Ma X, Lv C, Wang Q. Metformin alleviates oxidative stress and enhances autophagy in diabetic kidney disease via AMPK/SIRT1-FoxO1 pathway. Molecular and Cellular Endocrinology. 2020;500:110628. http://dx.doi.org/10.1016/j.mce.2019.110628
  105. Rizos T, Güntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, Reinhardt R, Hepp T, Kirchhof P, Aleynichenko E, Ringleb P, Hacke W, Veltkamp R. Continuous Stroke Unit Electrocardiographic Monitoring Versus 24-Hour Holter Electrocardiography for Detection of Paroxysmal Atrial Fibrillation After Stroke. Stroke. 2012;43(10):2689-2694. http://dx.doi.org/10.1161/strokeaha.112.654954
  106. Rizzo M, Sasso F, Marfella R, Siniscalchi M, Paolisso P, Carbonara O, Capoluongo M, Lascar N, Pace C, Sardu C, Passavanti B, Barbieri M, Mauro C, Paolisso G. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. Journal of Diabetes and its Complications. 2015;29(1):88-92. http://dx.doi.org/10.1016/j.jdiacomp.2014.09.002
  107. Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez J, Valdés M, Vicente V, Lip G. The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2013;62(23):2199-2204. http://dx.doi.org/10.1016/j.jacc.2013.08.1623
  108. Rosenstock J, Perkovic V, Johansen O, Cooper M, Kahn S, Marx N, Alexander J, Pencina M, Toto R, Wanner C, Zinman B, Woerle H, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George J, von Eynatten M, McGuire D. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA. 2019;321(1):69. http://dx.doi.org/10.1001/jama.2018.18269
  109. Ruff C, Giugliano R, Braunwald E, Hoffman E, Deenadayalu N, Ezekowitz M, Camm A, Weitz J, Lewis B, Parkhomenko A, Yamashita T, Antman E. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 2014;383(9921):955-962. http://dx.doi.org/10.1016/s0140-6736(13)62343-0
  110. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2010;:. http://dx.doi.org/10.1002/14651858.cd002967.pub4
  111. Schnabel R, Yin X, Gona P, Larson M, Beiser A, McManus D, Newton-Cheh C, Lubitz S, Magnani J, Ellinor P, Seshadri S, Wolf P, Vasan R, Benjamin E, Levy D. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. The Lancet. 2015;386(9989):154-162. http://dx.doi.org/10.1016/s0140-6736(14)61774-8
  112. Schoen T, Pradhan A, Albert C, Conen D. Type 2 Diabetes Mellitus and Risk of Incident Atrial Fibrillation in Women. Journal of the American College of Cardiology. 2012;60(15):1421-1428. http://dx.doi.org/10.1016/j.jacc.2012.06.030
  113. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal. Physiological Reviews. 2011;91(1):265-325. http://dx.doi.org/10.1152/physrev.00031.2009
  114. Scirica B. Prevalence, Incidence, and Implications of Silent Myocardial Infarctions in Patients With Diabetes Mellitus. Circulation. 2013;127(9):965-967. http://dx.doi.org/10.1161/circulationaha.113.001180
  115. Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, Zhao J, Zhao Y, Li G, Liu T. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. Cardiovascular Diabetology. 2019;18(1):. http://dx.doi.org/10.1186/s12933-019-0964-4
  116. Shi W, Zhang W, Zhang D, Ren G, Wang P, Gao L, Chen H, Ding C. Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis. Heart Rhythm. 2021;18(7):1090-1096. http://dx.doi.org/10.1016/j.hrthm.2021.03.007
  117. Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Research and Clinical Practice. 2019;150:8-16. http://dx.doi.org/10.1016/j.diabres.2019.02.014
  118. Soran H, Banerjee M, Mohamad J, Adam S, Ho J, Ismaeel S, Dhage S, Syed A, Abdulla I, Younis N, Malik R. Risk Factors for Failure of Direct Current Cardioversion in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation. BioMed Research International. 2018;2018:1-6. http://dx.doi.org/10.1155/2018/5936180
  119. Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovascular Diabetology. 2011;10(1):. http://dx.doi.org/10.1186/1475-2840-10-19
  120. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
  121. van Doorn S, Debray T, Kaasenbrood F, Hoes A, Rutten F, Moons K, Geersing G. Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis. 2017;15(6):1065-1077. http://dx.doi.org/10.1111/jth.13690
  122. Varma N, Marrouche N, Aguinaga L, Albert C, Arbelo E, Choi J, Chung M, Conte G, Dagher L, Epstein L, Ghanbari H, Han J, Heidbuchel H, Huang H, Lakkireddy D, Ngarmukos T, Russo A, Saad E, Saenz Morales L, Sandau K, Sridhar A, Stecker E, Varosy P. HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. Journal of the American College of Cardiology. 2020;76(11):1363-1374. http://dx.doi.org/10.1016/j.jacc.2020.06.019
  123. VEGLIO M, BRUNO G, BORRA M, MACCHIA G, BARGERO G, D’ERRICO N, PAGANO G, CAVALLO-PERIN P. Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort. Journal of Internal Medicine. 2002;251(4):317-324. http://dx.doi.org/10.1046/j.1365-2796.2002.00955.x
  124. Verma S, McMurray J. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108-2117. http://dx.doi.org/10.1007/s00125-018-4670-7
  125. Wang A, Green J, Halperin J, Piccini J. Atrial Fibrillation and Diabetes Mellitus. Journal of the American College of Cardiology. 2019;74(8):1107-1115. http://dx.doi.org/10.1016/j.jacc.2019.07.020
  126. Weih M, Amberger N, Wegener S, Dirnagl U, Reuter T, Einhäupl K. Sulfonylurea Drugs Do Not Influence Initial Stroke Severity and In-Hospital Outcome in Stroke Patients With Diabetes. Stroke. 2001;32(9):2029-2032. http://dx.doi.org/10.1161/str.32.9.2029
  127. White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G, Perez A, Fleck P, Mehta C, Kupfer S, Wilson C, Cushman W, Zannad F. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine. 2013;369(14):1327-1335. http://dx.doi.org/10.1056/nejmoa1305889
  128. Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A, Silverman M, Zelniker T, Kuder J, Murphy S, Bhatt D, Leiter L, McGuire D, Wilding J, Ruff C, Gause-Nilsson I, Fredriksson M, Johansson P, Langkilde A, Sabatine M. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2019;380(4):347-357. http://dx.doi.org/10.1056/nejmoa1812389
  129. Wu J, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, Neal B. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. 2016;4(5):411-419. http://dx.doi.org/10.1016/s2213-8587(16)00052-8
  130. Xiong Z, Liu T, Tse G, Gong M, Gladding P, Smaill B, Stiles M, Gillis A, Zhao J. A Machine Learning Aided Systematic Review and Meta-Analysis of the Relative Risk of Atrial Fibrillation in Patients With Diabetes Mellitus. Frontiers in Physiology. 2018;9:. http://dx.doi.org/10.3389/fphys.2018.00835
  131. Yoon M, Yang P, Jang E, Yu H, Kim T, Uhm J, Kim J, Sung J, Pak H, Lee M, Joung B, Lip G. Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study. Thrombosis and Haemostasis. 2019;119(10):1695-1703. http://dx.doi.org/10.1055/s-0039-1693516
  132. Zelniker T, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Journal of the American College of Cardiology. 2020;75(4):422-434. http://dx.doi.org/10.1016/j.jacc.2019.11.031
  133. Zhang Q, Liu T, Ng C, Li G. Diabetes Mellitus and Atrial Remodeling: Mechanisms and Potential Upstream Therapies. Cardiovascular Therapeutics. 2014;32(5):233-241. http://dx.doi.org/10.1111/1755-5922.12089
  134. Zhang Z, Zhang X, Korantzopoulos P, Letsas K, Tse G, Gong M, Meng L, Li G, Liu T. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. BMC Cardiovascular Disorders. 2017;17(1):. http://dx.doi.org/10.1186/s12872-017-0531-4
  135. Zhu W, Xiong Q, Hong K. Meta-Analysis of CHADS2 versus CHA2DS2-VASc for Predicting Stroke and Thromboembolism in Atrial Fibrillation Patients Independent of Anticoagulation. Texas Heart Institute Journal. 2015;42(1):6-15. http://dx.doi.org/10.14503/thij-14-4353
  136. Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen O, Woerle H, Broedl U, Inzucchi S. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. http://dx.doi.org/10.1056/nejmoa1504720
  137. ZIOLO M, MOHLER P. Defining the Role of Oxidative Stress in Atrial Fibrillation and Diabetes. Journal of Cardiovascular Electrophysiology. 2014;26(2):223-225. http://dx.doi.org/10.1111/jce.12560